Prostaglandin E 2 (PGE 2 ) is one of the most ubiquitous prostanoids in the kidney, where it may influence a wide range of physiologic functions. PGE 2 is generated through enzymatic metabolism of prostanoid endoperoxides by specific PGE synthases (PGES). Several putative PGES have been identified and cloned, including the membrane-associated, inducible microsomal PGES1 (mPGES1), which is expressed in the kidney. To evaluate the physiologic role of mPGES1 in the kidney, mice with targeted disruption of mPges1 gene were studied, with a focus on responses where PGE 2 has been implicated, including urinary concentration, regulation of blood pressure, and response to a loop diuretic. The absence of mPGES1 was associated with a 50% decrease in basal excretion of PGE 2 in urine (P < 0.001). In female but not male mPGES1-deficient mice, there was a reciprocal increase in basal excretion of other prostanoids. Nonetheless, urinary osmolalities were similar in mPges1 ؉/؉ and mPges1 ؊/؊ mice at baseline and after 12 h of water deprivation. Likewise, there were no differences in blood pressure between mPGES1-deficient and wild-type mice on control or high-or low-salt diets. The furosemide-induced increase in urinary PGE 2 excretion that was seen in wild-type mice was attenuated in mPGES1-deficient mice. However, furosemide-associated diuresis was reduced only in male, not female, mPGES1-deficient mice. Stimulation of renin by furosemide was not affected by mPGES1 deficiency. These data suggest that mPGES1 contributes to basal synthesis of PGE 2 , but there are other pathways that lead to renal PGE 2 synthesis. Moreover, there are significant gender differences in physiologic contributions of mPGES1 to control kidney function.
P rostaglandin E 2 (PGE 2 ) is one of the major prostanoid products generated by the kidney (1) , and it has diverse actions in the kidney, affecting both vascular tone and epithelial functions. For example, infusion of PGE 2 into the kidney commonly causes renal vasodilation (2, 3) . PGE 2 also modulates renal sodium and water excretion (1, 4) . Studies in isolated perfused nephron segments suggest that PGE 2 acting through E-prostanoid (EP) receptors such as EP1 may directly stimulate solute flux in renal epithelia (5) . PGE 2 may also influence water permeability in the distal nephron by opposing the actions of the stimulated G-protein-linked vasopressin receptor (4) . Moreover, enhanced generation of PGE 2 seems to contribute to the actions of loop diuretics (6) . It has been suggested that the propensity of nonsteroidal anti-inflammatory drugs (NSAID) to cause fluid retention and hypertension is due to inhibition of PGE 2 synthesis and consequent attenuation of its actions in the kidney (7) . PGE 2 is produced by a series of three enzymatic reactions: release of arachidonic acid from membrane phospholipids by the actions of phospholipases, conversion of arachidonic acid to unstable endoperoxide intermediates by cyclooxygenases (COX-1 and -2), and, finally, isomerization of PGH 2 to PGE 2 by terminal PGE synthases (PGES) (8) . PGES activity has been characterized biochemically in a number of tissues (9) . In most cell populations, the highest levels of specific PGES activity are associated with microsomal membrane fractions. Jakobsson and associates (10, 11) provided the first molecular characterization of a membrane-bound form of human PGES (mPGES1), showing that it is a member of the MAPEG (membrane-associated proteins involved in eicosanoid and glutathione metabolism) gene family. Expression of mPGES1 is highly inducible in states of injury and inflammation, often in parallel with expression of the inducible COX-2 (12, 13) . More recently, a second putative microsomal PGES (mPGES2) that can also generate PGE 2 from endoperoxides in vitro with high affinity and specificity was identified (14, 15) , but its capacity to generate PGE 2 in vivo is not clear. A third form of PGES has been isolated from cytoplasmic extracts (16) . This cytosolic PGES (cPGES) is expressed ubiquitously in a constitutive manner (16) . However, because of its low substrate affinity compared with the microsomal enzymes, the relevance of cPGES to the generation of PGE 2 in vivo has also been questioned.
Very little is known about the functions of the individual PGES in the kidney. Nonetheless, several studies have evalu-ated regional expression of mPGES1 in the kidney by in situ hybridization and immunocytochemistry (5, (17) (18) (19) . There is a general agreement among these studies that mPGES1 is expressed in the distal nephron from the connecting tubule through the cortical and medullary collecting duct (5, (17) (18) (19) . In this region, the distribution of mPGES1 parallels COX-1 expression (18, 19) . This distribution is consistent with previous studies indicating that the collecting duct is one of the nephron segments with the highest capacity for PGE 2 generation (1); abundant EP receptors, including EP1, EP3, and EP4, are also expressed in the collecting duct (4, 20) . Moreover, this segment of the nephron plays a critical role in the final adjustments of sodium excretion that have a major impact on fluid volume and BP homeostasis. However, the capacity of individual mPGES to influence renal functions is not known.
In studies that used mPGES1-deficient mice, we show here that mPGES1 contributes to basal and stimulated PGE 2 generation by the kidney. In male mice, augmented generation of PGE 2 by mPGES1 contributes to furosemide-induced diuresis. However, the relative contribution of mPGES1 to synthesis and functional consequences of PGE 2 in the kidney differs significantly between genders.
Materials and Methods

Animals
Production of mice with targeted disruption of the mPges1 gene has been described previously (21) . The mPges1 mutation was originally generated by homologous recombination in embryonic stem (ES) cells that were derived from DBA/1 inbred mice. Resulting chimeras were crossed with DBA/1 mice (Jackson Laboratory, Bar Harbor, ME) to generate inbred DBA/1 mice that bear the mPges1 mutation. Inbred DBA/1 mPges1 Ϫ/Ϫ and mPges1 ϩ/ϩ mice that were generated by intercrossing DBA/1 mPges1 ϩ/Ϫ mice were used for the studies described here. Mice were bred and maintained in the animal facility of the Durham Veterans Affairs Medical Center, and genotypes were determined as described previously (21) . The experimental procedures described next were approved by the respective institutional animal care and use committees of the Durham Veterans Affairs and Duke University Medical Centers.
Measurement of Systolic BP in Mice
Systolic BP was measured in conscious mice using a computerized tail-cuff system (Hatteras Instruments, Cary, NC) after 2 wk of daily training as described previously (22) . Data were recorded at baseline for 2 wk and then 5 d a week throughout the study period (one set of 10 measurements per day). Measurements with a SD Ͼ20 mmHg for the systolic BP were discarded. This method was validated previously and correlates well with direct measurements of intra-arterial pressure (23) . Baseline BP was measured on a control diet (0.4% NaCl). For determination of whether mPGES1 plays a role in BP homeostasis when dietary sodium intake is altered, BP was also monitored while mice were fed low-salt (LS; Ͻ0.02% NaCl) or high-salt (HS; 6% NaCl) diets for 3 wk (Harlan Teklad, Madison, WI). For these studies, the experimental groups consisted of both male mPges1 ϩ/ϩ (n ϭ 14) and mPges1 Ϫ/Ϫ (n ϭ 11) and female mPges1 ϩ/ϩ (n ϭ 6) and mPges1 Ϫ/Ϫ (n ϭ 7) mice.
Measurements of Urinary Prostanoid Excretion
Urinary prostanoid excretion was measured using individual ELISA assays. For measurement of PGE 2 , fresh urine samples were incubated in phosphate and carbonate buffer prepared with deionized water and incubated overnight at 37°C to convert intact PGE 2 and its intermediate metabolites to the stable PGE 2 metabolite (PGEM). Concentrations of PGEM in urine were determined by using a specific ELISA assay (Cayman Chemicals, Ann Arbor, MI). Previous studies have shown that urinary PGEM is a reliable indicator of urinary PGE 2 excretion in vivo (24) . Thromboxane B 2 (TxB 2 ), the stable metabolite of TxA 2 , and 6-keto-PGF 1␣ , the stable metabolite of prostacyclin (PGI 2 ), were measured in fresh urine using specific ELISA (Cayman Chemicals).
Assessment of Urinary Concentrating Capacity
Mice were placed in metabolic cages for collection of urine and monitoring of water intake. After an initial adaptation period, water intake and urine volumes were measured while the mice had free access to water. Urine of male and female mPges1 ϩ/ϩ and mPges1
mice was collected by bladder massage before and after a 12-h period of water deprivation. Urine osmolalities were then immediately measured using a vapor pressure osmometer (Wescor Instruments, Logan, UT) as described previously (25) .
Responses to the Loop Diuretic Furosemide
A 5-mg/ml furosemide (Sigma Chemicals, St. Louis, MO) solution was prepared in 10% DMSO in deionized water at pH 7. The 10% DMSO solution alone was used for control injections. Mice were administered an injection of 0.1 ml/10 g body wt of the furosemide solution or vehicle control and were immediately placed into individual metabolic cages, where they were provided free access to tap water. Urine was collected for exactly 4 h. Urine volumes were measured using tared containers, and urine sodium concentrations were measured using a flame photometer (Instrumentation Laboratory, Lexington, MA). For definition of the contribution of prostanoids to the furosemide response, separate groups of inbred male and female mice were given diclofenac (10 mg/kg; Sigma Chemicals) in drinking water for 24 h before the furosemide injection.
Reverse Transcription and Real-Time Quantitative PCR
Total RNA was extracted from whole kidneys using TriReagent (Sigma) according to the manufacturer's protocol. RNA was DNAsetreated using Turbo DNA-free (Ambion, Austin, TX) to remove genomic DNA contamination. RNA yield was quantified by ultraviolet spectrophotometry, and integrity was verified by 1% agarose gel electrophoresis and staining with ethidium bromide. Only RNA with A260/280Ͼ1.7 and displaying no significant degradation was used for reverse transcription.
cDNA were synthesized from 5 g of total RNA using random hexamers and SuperScript II reverse transcriptase (RT; Invitrogen, Carlsbad, CA). "No RT" samples that lacked RT were prepared during each RT reaction for use as negative controls during PCR. Real-time quantitative PCR was performed using the fluorogenic 5Ј-exonuclease assay (26) . Primers and dual-labeled probes (5Ј-FAM, 3Ј-TAMRA) targeting mPGES1 (assay ID Mm00452105_m1; exons 2 to 3 boundary, amplicon length 87 bp), mPGES2 (assay ID Mm00460181_m1; exons 2 to 3 boundary, amplicon length 73 bp), cPGES (assay ID Mm00727367_s1; exon 8, amplicon length 70 bp), COX-1 (assay ID Mm00477214_m1; exons 2 to 3 boundary, amplicon length 66 bp), and COX-2 (assay ID Mm00478374_m1; exons 5 to 6 boundary, amplicon length 80 bp) were purchased from Applied Biosystems (Foster City, CA). PCR reactions were performed in duplicate on an iCycler real-time detection system (BioRad, Hercules, CA). cDNA and negative control (no RT, water) templates (1 l) were added to 20 l PCR reaction mixtures that consisted of 1ϫ ABI TaqMan Universal PCR master mix and either 1ϫ human eukaryotic 18S rRNA primer-probe mix or 1ϫ primer-probe mix for the gene of interest. Gene expression was quantified using the two standard curve method for relative quantification (27) . Briefly, a five-point dilution series of positive control cDNA was prepared, and standard curves of threshold cycle versus relative template concentration were generated for the gene of interest and housekeeping gene (18S rRNA). Template concentrations of unknown samples were then determined, based on their threshold cycle values, from these standard curves. Expression of mPGES1, mPGES2, cPGES, COX-1, and COX-2 was normalized to 18S rRNA expression in the same tissue.
In a separate groups of mice, furosemide or vehicle was administered as described. Four hours later, kidneys was harvested, RNA was extracted, and expression of mPGES1 and COX-2 was determined.
Furosemide-Stimulated Renin Expression
To examine the role of mPGES1 in regulation of renin, we compared baseline and furosemide-stimulated renin expression in male mPges1 ϩ/ϩ and mPges1 Ϫ/Ϫ mice. Groups of mice of were given furosemide (2.5 mg/kg per d) in the drinking water (n ϭ 12) or tap water alone (n ϭ 7). After 5 d, kidneys were harvested, RNA was isolated, and renin mRNA levels were determined by real-time PCR as described.
Statistical Analyses
The values for each parameter within a group are expressed as the means Ϯ the SEM. For comparisons between groups, statistical significance was assessed using ANOVA followed by unpaired t test adjusted for multiple comparisons. A paired t test was used for comparisons within groups.
Results
mPGES1 and Urinary Prostanoid Excretion
To determine the contribution of mPGES1 to urinary prostanoid excretion, we measured excretion of PGE 2 , TXA 2 , and PGI 2 metabolites in urine that was collected from mPges1 Ϫ/Ϫ and mPges1 ϩ/ϩ mice. In general, as shown in Figure 1 , urinary excretion of all prostanoid moieties was significantly higher in female compared with male mice irrespective of mPges1 genotype (P Ͻ 0.001 for urinary PGEM excretion and TxB 2 excretion between male and female mice; P Ͻ 0.05 for urinary 6 keto-PGF 1␣ ). Excretion of PGE 2 metabolites was reduced by approximately 50% in male mPges1 Ϫ/Ϫ mice compared with wild-type (WT) controls (from 368 Ϯ 50 to 196 Ϯ 34 pg/24 h; P Ͻ 0.01; Figure 1A ); 24-h urine volume was similar in both groups (1.1 Ϯ 0.6 versus 1.1 Ϯ 0.5 ml). In contrast, urinary excretion of TxB 2 (1579 Ϯ 244 versus 1509 Ϯ 253 pg/24 h) or 6 keto-PGF1␣ (1941 Ϯ 417 versus 1422 Ϯ 132 pg/24 h) were unaffected by the mPges1 mutation in male mice. As shown in Figure 1B 
Expression of PGES and Cyclooxygenases in Kidneys of mPGES1-Null Mice
To determine the effect of mPGES1 deletion on other components of the prostanoid synthetic pathway and to test for Figure 1 . Microsomal prostaglandin E synthase 1 (mPGES1) and urinary prostanoid excretion. Prostanoid excretion was determined in 24-h urine collections from male wild-type (WT; Ⅺ; n ϭ 15) and mPges1 Ϫ/Ϫ (f; n ϭ 11) mice (A) and female WT (Ⅺ; n ϭ 6) and mPges1 Ϫ/Ϫ (f; n ϭ 7) mice (B) and is expressed in pg/24 h. Prostaglandin E 2 (PGE 2 ) metabolite excretion is decreased by 50% in both male and female mPges1 Ϫ/Ϫ mice. Thromboxane B 2 (TxB 2 ) and 6 keto-PGF 1␣ are increased in female mPges1 Ϫ/Ϫ versus female WT mice (P Ͻ 0.05). Prostanoid excretion is increased in female compared with male mice regardless of gender and genotype (P Ͻ 0.001 versus male mice for PGEM and TxB 2 ; P Ͻ 0.01 for 6 keto-PGF 1␣ ). *P Ͻ 0.01 versus WT; † P Ͻ 0.05 versus WT; ‡ P Ͻ 0.001 versus male mice; § P Ͻ 0.01 versus male mice.
potential gender effects on their expression in the kidney, we used real-time quantitative RT-PCR to compare mRNA abundance of COX-1, COX-2, mPGES1, mPGES2, and cPGES in groups of male and female mPges1 ϩ/ϩ and mPges1 Ϫ/Ϫ mice.
Among WT mice, there seemed to be a trend toward greater COX-1 mRNA abundance in WT female compared with male mice, but the difference did not reach statistical significance (Figure 2A) . Conversely, levels of COX-2 mRNA in kidneys of WT female mice were approximately two-fold higher than those of WT male mice (P Ͻ 0.01), corresponding with the significantly higher urinary prostanoid excretion that we observed in female mice. Similarly, as shown in Figure 2B , levels of mPGES1 mRNA were also significantly higher in female compared with male mPges1 ϩ/ϩ mice (P Ͻ 0.01). There were no differences in expression of mPGES2 and cPGES between male and female WT mice. As shown in Figure 2A , the absence of mPGES1 had no effect on COX-1 expression in male or female mice. By contrast, COX-2 mRNA expression was increased significantly in mPGES1 Ϫ/Ϫ male mice compared with WT male controls (P ϭ 0.01), and these levels were similar to those of mPGES1 ϩ/ϩ female mice. However, the absence of mPGES1
did not cause further augmentation of COX-2 expression in female mice as COX-2 mRNA expression was similar in female mPges1 ϩ/ϩ and mPges1 Ϫ/Ϫ mice. As expected, mPGES1 expression was not detected in kidneys from male or female mPges1 Ϫ/Ϫ mice ( Figure 2B) . Moreover, the absence of mPGES1 had no effect on expression of the other putative PGES, mPGES2 or cPGES.
mPGES1 and Urinary Concentration
Previous studies have suggested that PGE 2 may directly oppose the actions of vasopressin to promote water flux in the distal nephron, thereby modulating urinary concentrating mechanisms (4). To determine whether mPGES1 might contribute to this response, we compared urinary osmolality in mPges1 Ϫ/Ϫ and mPges1 ϩ/ϩ mice with free access to water and after 12-h of water deprivation. Baseline urine osmolalities were similar in mPges1 Ϫ/Ϫ (n ϭ 8) and mPges1 ϩ/ϩ (n ϭ 12) mice (1672 Ϯ 180 versus 1876 Ϯ 134 mOsm; NS). After 12 h of water deprivation, urine osmolalities increased significantly in both groups (P Ͻ 0.001), and the maximal urine osmolalities after thirsting were virtually identical in mPges1 Ϫ/Ϫ and mPges1 ϩ/ϩ mice (3431 Ϯ 109 versus 3461 Ϯ 73 mOsm; NS).
Thus, the absence of mPGES1 does not significantly alter the capacity of the renal concentrating mechanisms.
Role of mPGES1 in BP and Adaptation to Altered Dietary Sodium Intake
On the control (0.4% NaCl) diet, there were no differences in BP between male (117 Ϯ 2 versus 118 Ϯ 2 mmHg) and female (121 Ϯ 1 versus 119 Ϯ 2 mmHg) mPges1 Ϫ/Ϫ and mPges1 ϩ/ϩ mice, respectively. BP was not significantly affected by low-salt feeding in male (120 Ϯ 2 versus 118 Ϯ 2 mmHg) or female (120 Ϯ 1 versus 121 Ϯ 2 mmHg) mPges1 Ϫ/Ϫ and mPges1 ϩ/ϩ mice, respectively. Feeding the high-salt diet caused BP to increase significantly in all of the groups (P Ͻ 0.0001 by paired t test), but the magnitude of BP increases was similar in the WT and mPGES1-deficient mice so that BP were similar at the end of the high-salt period in male (133 Ϯ 3 versus 129 Ϯ 2 mmHg) and female (132 Ϯ 3 versus 134 Ϯ 3 mmHg) mPges1 Ϫ/Ϫ and mPges1 ϩ/ϩ mice, respectively.
Role of mPGES1 in the Diuretic Response to Furosemide
To determine whether mPGES1 might be the source of the enhanced PGE 2 generation with furosemide and to define its contribution to facilitating the actions of furosemide in the kidney, we compared furosemide responses in groups of male and female mPges1 ϩ/ϩ and mPges1 Ϫ/Ϫ mice. As shown in Figure 3 , administration of furosemide caused a brisk diuresis in male WT mice, with urine volume increasing from 0.31 Ϯ 0.07 ml/4 h before treatment to 1.2 Ϯ 0.07 ml/4 h after furosemide (P Ͻ 0.001). Urine sodium also increased significantly from 23 Ϯ 7 to 147 Ϯ 8 mol/4 h (P Ͻ 0.001). Along with this diuresis and natriuresis, excretion of PGE 2 metabolites increased in male WT mice from 73 Ϯ 18 to 152 Ϯ 28 pg/4h (P Ͻ 0.05), whereas excretion of TxB 2 and 6 keto-PGF 1␣ was unaffected ( Figure 4) . Furosemide had very similar effects in WT female mice (Figure 3) . Urine volume increased from 0.26 Ϯ 0.07 ml/4 h before treatment to 1.24 Ϯ 0.1 ml/4h with furosemide (P Ͻ 0.001). Sodium excretion also increased from 13.6 Ϯ 4 to 132 Ϯ 12 mol/4 h (P Ͻ 0.001; Figure 3) . Although basal excretion of PGE 2 was higher in the WT female compared with male mice, PGE 2 excretion increased further after furosemide, from 889 Ϯ 196 to 1664 Ϯ 122 pg/4 h (P Ͻ 0.01). Similar to male mice, excretion of TxB 2 and 6 keto-PGF 1␣ was not altered by furosemide in female WT mice (Figure 4) .
To determine whether furosemide effected expression of synthetic enzymes in the PGE 2 pathway, we compared mRNA levels for mPGES1 in WT DBA/1 mice 4 h after administration of vehicle or furosemide. Levels of mPGES1 mRNA were similar in vehicle-(1.48 Ϯ 0.22) and furosemide-treated mice (1.32 Ϯ 0.10), suggesting that furosemide had no effect on mPges1 expression during the interval tested.
As shown in Figure 3 , compared with male mPges1 ϩ/ϩ mice, response to furosemide was significantly attenuated in the male mPges1 Ϫ/Ϫ mice. Urine flow (0.95 Ϯ 0.05 versus 1.2 Ϯ 0.07 ml/4 h; P Ͻ 0.05) and sodium excretion (117 Ϯ 6 versus 147 Ϯ 8 mol/4 h; P Ͻ 0.01) after furosemide injection were approximately 20% lower in male mPGES1-deficient mice than in WT controls. However, both urine flow and sodium excretion were increased significantly compared with baseline conditions (P Ͻ 0.001). Furthermore, unlike in WT male mice, furosemide had no effect on PGE 2 metabolite excretion in the male mPges1 Ϫ/Ϫ mice (73 Ϯ 18 versus 74 Ϯ 10 pg/4 h). Accordingly, as shown in Figure 4 , excretion of PGE 2 metabolites after administration of furosemide was significantly lower in the male mPGES1-deficient mice (74 Ϯ 10 pg/4 h) than in male, WT controls (152 Ϯ 28 pg/4 h; P Ͻ 0.05). Unlike the male mPges1 Ϫ/Ϫ mice, the extent of furosemideinduced diuresis was not altered in female mPges1 Ϫ/Ϫ mice. As shown in Figure 3 , urine flow (0.28 Ϯ 0.03 versus 1.22 Ϯ 0.07 ml/4 h; P Ͻ 0.001) and sodium excretion (18 Ϯ 7 versus 145 Ϯ 11 mol/4 h; P Ͻ 0.001) increased significantly. Moreover, after furosemide, urine flow (1.22 Ϯ 0.07 versus 1.24 Ϯ 0.1 ml/4 h) and sodium excretion (145 Ϯ 11 versus 132 Ϯ 12 mol/4 h) were virtually identical in female mPges1 ϩ/ϩ and mPges1 Ϫ/Ϫ mice.
As shown in Figure 4 , despite this preservation of furosemide diuresis in the mPges1 Ϫ/Ϫ female mice, PGE 2 metabolite excretion was modestly but not significantly augmented after furo- semide (387 Ϯ 85 versus 585 Ϯ 65 pg/4 h; NS). Thus, compared with female WT mice, PGE 2 metabolite excretion after furosemide was significantly lower in the mPGES1-deficient female mice (599 Ϯ 55 versus 1664 Ϯ 122 pg/4 h; P Ͻ 0.001). Nonetheless, as a consequence of the marked gender difference in basal prostanoid excretion, the levels of PGE 2 excretion after furosemide were significantly higher in mPGES1-deficient female mice than in WT male controls (585 Ϯ 65 versus 301 Ϯ 52 pg/4 h; P Ͻ 0.01). Although PGE 2 excretion was not significantly affected by furosemide, excretion of both TxB2 (840 Ϯ 65 versus 2143 Ϯ 4 pg/4 h; P Ͻ 0.05) and 6 keto-PGF 1␣ (881 Ϯ 166 versus 4397 Ϯ 637 pg/4 h; P Ͻ 0.01) increased after furosemide in the female mPGES1-deficient mice (Figure 4) .
To explore further the relationship between furosemide-induced diuresis and prostanoid generation in female mice, we examined the consequences of a more complete inhibition of prostanoids by pretreating mice with the COX inhibitor diclofenac (10 mg/kg). Pretreatment of female WT mice with diclofenac caused a significant attenuation of furosemide-induced natriuresis and diuresis in WT female mice ( Figure 5, A and B) . Urine flow was decreased by approximately 35%, from 1.38 Ϯ 0.13 ml/4 h without pretreatment to 0.89 Ϯ 0.09 ml/4 h with diclofenac (P Ͻ 0.05). Sodium excretion was similarly reduced from 145 Ϯ 13 to 108 Ϯ 12 mol/4 h (P Ͻ 0.05) with the COX inhibitor. As shown in Figure 5C , along with its effects on the diuretic response, diclofenac caused a broad inhibition of furosemide-stimulated prostanoid excretion (575 Ϯ 48 versus 2044 Ϯ 252 pg/4 h for PGE 2 
Furosemide-Stimulated Renin Expression
PGE 2 is a potent secretagogue for renin, where it operates as part of a signaling pathway that includes COX-2. In the macula densa, reduced solute flux through the Na-K-2Cl co-transporter (NKCC2) regulates the PGE 2 -dependent signal for renin (28) . Discussion PGE 2 is a key product of the COX pathway of arachidonic acid metabolism. This lipid mediator has diverse actions that include cytoprotective functions in the gastrointestinal tract, regulating smooth muscle tone in airways and vasculature, modulating the immune system, and triggering febrile responses in the brain (29 -31) . PGE 2 is a major arachidonic acid metabolite in the kidney, where it may affect control of renal blood flow, sodium excretion, and BP (1). It is produced by a series of three enzymatic reactions: release of arachidonic acid from membrane phospholipids by the actions of phospholipases, conversion of arachidonic acid to unstable endoperoxide intermediates by COX-1 and -2, and, finally, isomerization of PGH 2 to PGE 2 by terminal PGES. The temporal and spatial properties of PGE 2 synthesis are determined by the regulated expression of each of the enzymes involved in this cascade. Of the several putative PGES that have been described, mPGES1 is the best characterized, and a role for mPGES1 in inflammation and febrile responses has been clearly demonstrated (21, 32, 33) . Although mPGES1 is expressed in the kidney (17) (18) (19) 34) , its contribution to PGE 2 synthesis in the kidney and to the consequent regulation renal functions has not been characterized previously.
Relative to other COX products, PGE 2 is generated in substantial quantities by the kidney (1). Major sites of PGE 2 generation by the kidney are renal medullary interstitial cells and collecting duct (1, (35) (36) (37) . Studies using in situ hybridization and immunocytochemistry have documented mPGES1 expression in the distal nephron from the connecting tubule through the cortical and medullary collecting duct (17) (18) (19) 34) . In this region, the distribution of mPGES1 parallels expression of COX-1 (18, 19) .
Our studies suggest that mPGES1 makes a nonredundant contribution to renal PGE 2 production, because urinary PGE metabolite excretion is reduced by approximately 50% in mPGES1-deficient animals in the basal state. Our findings are consistent with another recent article that showed a marked reduction of urinary PGE 2 metabolite excretion, measured by gas chromatography-mass spectrometry, in mPGES1-deficient mice compared with controls (38) . Although the magnitude of the impact of mPGES1 deficiency was similar across genders, in mPges1 Ϫ/Ϫ female but not mPges1 Ϫ/Ϫ male mice, there was a proportional increase in excretion of other prostanoids, including PGI 2 (prostacyclin). This may result from shunting of endoperoxides toward other prostanoid synthetic pathways. This phenomenon has been observed in other circumstances when prostanoid synthetic enzymes are genetically deleted (39) or pharmacologically inhibited (40) . Because PGI 2 and PGE 2 have some redundant functions (8) , this increase in PGI 2 generation might act as a compensatory mechanism to ameliorate the physiologic consequences of mPGES1 deficiency. Similar reductions in basal PGE 2 generation with shunting have been reported in other tissue preparations from mPges1 Ϫ/Ϫ mice (41, 42) . We also found prominent differences in renal prostanoid generation between male and female mice in our studies with basal levels of prostanoid excretion that are almost fourfold higher in female than male mice. These were accompanied by enhanced expression of mRNA for synthetic enzymes, including COX-2 and mPGES1 in kidneys of female compared with male mice. Although our data assign a unique role for mPGES1 in renal PGE 2 generation, we find significant residual levels of PGE 2 production in the absence of mPGES1. Moreover, we and others have previously shown that ductus arteriosus closure is dependent on activation of the EP4 receptor for PGE 2 (43, 44) , yet mPGES1-deficient mice undergo normal closure of the ductus arteriosus (21, 32) . Taken together, these data indicate that there are alternative, mPGES1-independent pathways for PGE 2 synthesis in the intact animal. The nature of these pathways is not clear, but our unpublished data suggest that another puta- tive PGE synthase, mPGES2, does not make a significant contribution to PGE 2 generation in vivo (Jania et al., submitted). Among its wide range of physiologic actions, PGE 2 has a number of effects that could affect BP homeostasis. It is a potent vasodilator in both the peripheral (45) and renal vasculature (46) . Moreover, PGE 2 has potent natriuretic effects in the kidney through direct epithelial effects on salt and water transport and as a consequence of its hemodynamic actions to increase renal blood flow (3, 8) . Accordingly, it has been suggested that inhibition of PGE 2 could explain the actions of NSAID and COX-2 inhibitors to cause edema and hypertension. However, PGE 2 is a potent secretogogue for renin, and the consequences of activation of the renin-angiotensin system by PGE 2 are in direct opposition to its effects on renal vasculature and epithelia that lead to vasodilation and natriuresis. However, our data do not support a role for mPGES1 in furosemide-stimulated renin release. These findings are consistent with previous studies that suggested that PGI 2 , acting through the I-prostanoid (IP) receptor, may be the critical pathway mediating stimulation of renin with NKCC2 blockade (47) .
The role of individual pathways for PGE 2 synthesis in regulating BP is not known. Our data suggest that mPGES1 does not play a major role in BP homeostasis, because BP was virtually identical in mPges1 ϩ/ϩ and mPges1 Ϫ/Ϫ mice across a range of dietary sodium intakes. This finding is consistent with the recent report by Cheng et al. (38) , who also found no difference in BP between mPges1 Ϫ/Ϫ and WT control mice on either normal-or high-salt diet. Furthermore, our previous studies implicated alterations in PGI 2 in NSAID-associated hypertension (48) . Nonetheless, it is still possible that mPGES1 might have played a role in modulating BP and vascular tone on a different genetic background or in models of hypertension. Among its actions in the kidney, PGE 2 may influence water permeability in the distal nephron by opposing the actions of the Gs-linked vasopressin receptor (49) . Because of its linkage to inhibitory G-protein (Gi) and its high levels of expression in renal medulla, the EP3 receptor was suggested as a candidate to mediate the actions of PGE 2 in opposing vasopressin-stimulated water flow (50) , yet in a previous study, we found only subtle changes in urinary concentrating and diluting mechanisms in EP3-deficient mice (51) . In these studies, we find that the absence of mPGES1 has no effect on urinary concentrating capacity. Accordingly, insofar as PGE 2 may modulate vasopressin actions in the intact animal, mPGES1 is not absolutely required. It is possible that the residual level of PGE 2 generated in kidneys of mPGES1 mice is sufficient to fulfill this function. Alternatively, the capacity of PGE 2 to influence vasopressin actions in vivo may be less robust than suggested by studies in cell culture or isolated perfused nephron segments (50, 52) . However, alterations in urinary concentrating capacity did not become apparent in cytosolic phospholipase A2 (cPLA2)-deficient mice until Ͼ320 d of age (24) , and our studies were carried out in mice that were Ͻ6 mo of age.
Evidence from clinical studies indicates a contribution of PGE 2 to the sodium excretion that is induced by furosemide (6,53). For example, in healthy humans, a correlation was found between sodium excretion and the furosemide-induced increment in PGE 2 (53) . Our studies indicate that mPGES1 is the primary source of furosemide-stimulated PGE 2 release, because the enhancement of PGE 2 generation after furosemide is virtually abolished in mPGES1-deficient mice. Blockade of NKCC2 by furosemide stimulates prostanoid generation in part via upregulation of COX-2 (54). Our data suggest that mPGES1 is also linked to this pathway and, at least in males, directly contributes to diuresis and natriuresis. However, we find no effect of furosemide on mPges1 expression in the kidney, suggesting that stimulation of prostanoid excretion by furosemide occurs at a level upstream of mPGES1. mPGES1 is also essential for furosemide-stimulated PGE 2 generation in female mice. However, this augmentation of PGE 2 generation is not required for the full diuretic response in female mice. Because COX inhibition reduces the extent of furosemide diuresis in WT female mice, there are at least two possible explanations for the preserved furosemide response in female mPGES1-deficient mice. First, despite their failure to augment PGE 2 excretion with furosemide, the levels of PGE 2 excretion in female mPGES1-deficient mice exceed those seen in male WT mice after furosemide administration. Thus, there may be a threshold level of PGE 2 excretion required to facilitate diuresis with furosemide, and this level may be exceeded even in the basal state in mPGES1-deficient female mice. Alternatively, the increase in PGI 2 generation that is seen in the female mPGES1-deficient mice may act as a compensatory mechanism to blunt the impact of their failure to augment PGE 2 generation after furosemide.
Until the recent development of mPGES1-deficient mouse lines (21, 32) , very little was known about the in vivo functions of the different forms of PGES. Studies using mPges1 Ϫ/Ϫ mice indicate that mPGES1 is responsible for the late phase of PGE 2 synthesis during inflammation via a pathway that depends on COX-2 (21, 32) . Febrile responses to LPS are also mediated by mPGES1 (33) , and mPGES1 is the source of PGE 2 that facilitates acute inflammatory pain (21) . Expression of mPGES1 is markedly upregulated in synovial tissues in arthritis (12, 55) , contributing to the pathogenesis of joint inflammation and swelling (21) . Taken together, these observations suggest that inhibition of mPGES1 might be useful for the treatment of inflammation and pain, providing a more precise therapeutic target than NSAID or COX-2 inhibitors. Nonetheless, the utility of this approach would depend on whether some of the untoward effects that are associated with global COX inhibition, such as gastrointestinal toxicity, hypertension, and adverse renal effects, would be avoided by specific mPGES1 inhibition. Our findings predict that there would be a preservation of a residual capacity for PGE 2 generation in the kidney with mPGES1 inhibition that might protect against renal complications of COX inhibition, such as hypertension. However, some resistance to loop diuretics might be expected.
